Navigation Links
New Afatinib (BIBW 2992) Data in Non-Small Cell Lung Cancer Patients Presented at the 2010 ESMO Congress
Date:10/11/2010

further benefit from afatinib beyond progression when given in combination with chemotherapy.

Afatinib is also being investigated in breast and head and neck cancer, as well as in a variety of additional solid tumors.

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim is committed to discovering and developing novel cancer treatments. This commitment is underpinned by using advances in science to develop a range of targeted therapies in areas of medical need, including various solid tumors and haematological cancers.

The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition.  Afatinib is currently in phase III clinical development in NSCLC.  Apart from afatinib, Boehringer Ingelheim's late-stage oncology portfolio includes BIBF 1120, also in phase III development for the treatment of patients in two different tumor types, advanced NSCLC and ovarian cancer.  BIBF 1120 is an orally-administered investigational triple angiokinase inhibitor that targets three of the receptor tyrosine kinases shown to aid in the regulation of angiogenesis:  fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR).

In the area of cell-cycle kinase inhibition, Boehringer Ingelheim is developing inhibitors of polo-like kinase 1 (Plk1), a protein that is involved in the processes of cell division. These molecules are in the earlier stages of clinical development
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
5. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
8. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015 According ... Hybridization Market Study (2014-2019) by Type (DNA ISH, RNA ... By End User (Hospitals, Pharma & Biotech Companies, Research ... at $554.4 million 2014 and is estimated to reach ... during the forecast period, 2014 to 2019. ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v4wlnk/key_pharma_news ) ... Pharma News Issue" newsletter to their offering. ... burgeoning oncology pipeline and serves as a statement ... in 2015, with a large-scale potentially transformative acquisition ... Key Pharma News covers all major developments in ...
(Date:7/27/2015)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that it ... June 30, 2015, on Thursday, August 6, 2015, after the ... 4:30 p.m. Eastern Time to discuss the financial results and ... Conference Call Details To access the live conference call on ... please dial 877-703-6106 from the United States ...
Breaking Medicine Technology:Global In-Situ Hybridization Market to be Worth $681.0 Million by 2019 2Global In-Situ Hybridization Market to be Worth $681.0 Million by 2019 3Key Pharma News Issue - Gilead will make further oncology deals in 2015 2Key Pharma News Issue - Gilead will make further oncology deals in 2015 3Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2
... , WALTHAM, Mass., Dec. 14 According ... technology market intelligence, increased use of safety devices for small-bore ... driver of the enteral feeding device markets in both the ... for Enteral Feeding Devices 2010 report finds that the ...
... Colo., Dec. 14 Manchester Pharmaceuticals, Inc.(TM) announced today ... On October 22, 2009, the US Food and Drug ... suffering from gallstones in whom surgery poses an unacceptable ... Chenodal prescriptions have started to be dispensed to patients ...
Cached Medicine Technology:Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3Manchester Announces Availability of Chenodal(TM) 2
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... The heroin ... country, reported WCNC on July 7th. The rate for heroin usage has ... has gone down considerably, and is a less expensive alternative for those with an ...
(Date:7/27/2015)... ... July 27, 2015 , ... In a piece ... personal side of plastic surgery and explained why people should not shy away from ... for the excesses of the few and celebrate it for the modern wonder that ...
(Date:7/27/2015)... Plains, NJ (PRWEB) , ... July 27, 2015 , ... ... tendon of an accomplished athlete. “The patient is high-end athlete, whose accomplishments include ... after 8 months of Achilles tendon pain, which was diagnosed as tendinitis. I ...
(Date:7/27/2015)... , ... July 27, 2015 , ... ... including emergency notification and mobile collaboration, announced today the ... user interface, language localization and other feature enhancements. , This software release gives ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... and in-depth research report. The report provides basic information such as calcium ... This report covers the global (US, Europe, Japan etc) industry analysis like ...
Breaking Medicine News(10 mins):Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3Health News:Send Word Now Announces Release of New User Interface for its Award-Winning Mass Notification Service 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3
... understanding of dopamine release from nerve cells, findings that ... treating Parkinson,s Disease. People with Parkinson,s Disease ... movement and, in extreme cases, a loss of physical ... of dopamine producing nerve cells in the brain. ...
... finds increase lowers chance of hospitalization or death ... with heart failure, high doses of the drug losartan, ... admission and death, a new study shows. , Though ... the study focused on whether dose level makes a ...
... ... expertise offers a winning combination to companies with large sales forces. , ... Chicago, IL (PRWEB) November 18, ... , knowledge and collaboration platform, and ELA Consulting Group , sales effectiveness and ...
... ... of resources to help community health officials make use of the company’s new mapping ... white paper and a free webinar, each demonstrate how Depiction can be used as ... ...
... A ... a new technique available at Houston weight loss surgery practice Texas Laparoscopic ... surgical treatment for morbid obesity. , ... (Vocus) November 18, 2009 -- Houston-based Texas Laparoscopic Consultants is a ...
... ... families learn five steps for creating joyful holidays and family celebrations. , ... (PRWEB) November 18, 2009 -- PAIRS Foundation is ... joyful holidays and family celebrations. , ,"Holidays can be a time of wonderful celebration, sharing ...
Cached Medicine News:Health News:Findings that should speed the development of drugs for Parkinson's disease 2Health News:Heart Failure Drug May Help More in Higher Doses 2Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 2Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 3Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 4Health News:Community Health Officials Can Improve Real Time H1N1 Information Sharing with New Resources from Depiction, Inc. 2Health News:Community Health Officials Can Improve Real Time H1N1 Information Sharing with New Resources from Depiction, Inc. 3Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 2Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 3Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 4Health News:Five Steps to Happy Family Gatherings at Holiday Time 2
The Nervous System Flash Cards product uses the time tested content and images from BryanEdwards.com and displays the necessary images to demonstrate the nervous system....
... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
Pocket Medicine's Cardiology Bundle includes the following 4 applications: Treatment Strategies in Cardiovascular Medicine, Treatment Strategies in Interventional Cardiology, Treatment Strategies in ...
Medicine Products: